Burkholz, S.R.; Herst, C.V.; Carback, R.T.; Harris, P.E.; Rubsamen, R.M.
Survivin (BIRC5) Peptide Vaccine in the 4T1 Murine Mammary Tumor Model: A Potential Neoadjuvant T Cell Immunotherapy for Triple Negative Breast Cancer: A Preliminary Study. Vaccines 2023, 11, 644.
https://doi.org/10.3390/vaccines11030644
AMA Style
Burkholz SR, Herst CV, Carback RT, Harris PE, Rubsamen RM.
Survivin (BIRC5) Peptide Vaccine in the 4T1 Murine Mammary Tumor Model: A Potential Neoadjuvant T Cell Immunotherapy for Triple Negative Breast Cancer: A Preliminary Study. Vaccines. 2023; 11(3):644.
https://doi.org/10.3390/vaccines11030644
Chicago/Turabian Style
Burkholz, Scott R., Charles V. Herst, Richard T. Carback, Paul E. Harris, and Reid M. Rubsamen.
2023. "Survivin (BIRC5) Peptide Vaccine in the 4T1 Murine Mammary Tumor Model: A Potential Neoadjuvant T Cell Immunotherapy for Triple Negative Breast Cancer: A Preliminary Study" Vaccines 11, no. 3: 644.
https://doi.org/10.3390/vaccines11030644
APA Style
Burkholz, S. R., Herst, C. V., Carback, R. T., Harris, P. E., & Rubsamen, R. M.
(2023). Survivin (BIRC5) Peptide Vaccine in the 4T1 Murine Mammary Tumor Model: A Potential Neoadjuvant T Cell Immunotherapy for Triple Negative Breast Cancer: A Preliminary Study. Vaccines, 11(3), 644.
https://doi.org/10.3390/vaccines11030644